Is Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) a buy in 2026?
No. Cardio Diagnostics Holdings, Inc. is one to avoid for now, per the Compass.
A $5M market cap epigenetics company burning cash faster than it earns revenue. Interesting science, brutal math, near-certain dilution ahead.
Where CDIO is headed
Cardio Diagnostics is a $5 million market cap company selling epigenetic blood tests for coronary heart disease risk. The science is real. The commercial reality is that TTM revenue is so small that a +185% growth rate still leaves the business generating a rounding error against a $3.9 million cash burn. When operating margin reads negative 66,000%, you are not looking at a company, you are looking at a research project with a ticker.
Read the full Compass Direction on CDIO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $1.56).
See the full CDIO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) a buy in 2026?
No. Cardio Diagnostics Holdings, Inc. is one to avoid for now, per the Compass. A $5M market cap epigenetics company burning cash faster than it earns revenue. Interesting science, brutal math, near-certain dilution ahead.
What is CDIO's Compass Score?
Cardio Diagnostics Holdings, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for CDIO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CDIO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.